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Chronic kidney disease induces 
a systemic microangiopathy, 
tissue hypoxia and dysfunctional 
angiogenesis
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Chronic kidney disease (CKD) is associated with excessive mortality from cardiovascular disease (CVD). 
Endothelial dysfunction, an early manifestation of CVD, is consistently observed in CKD patients 
and might be linked to structural defects of the microcirculation including microvascular rarefaction. 
However, patterns of microvascular rarefaction in CKD and their relation to functional deficits in 
perfusion and oxygen delivery are currently unknown. In this in-vivo microscopy study of the cremaster 
muscle microcirculation in BALB/c mice with moderate to severe uremia, we show in two experimental 
models (adenine feeding or subtotal nephrectomy), that serum urea levels associate incrementally with 
a distinct microangiopathy. Structural changes were characterized by a heterogeneous pattern of focal 
microvascular rarefaction with loss of coherent microvascular networks resulting in large avascular 
areas. Corresponding microvascular dysfunction was evident by significantly diminished blood 
flow velocity, vascular tone, and oxygen uptake. Microvascular rarefaction in the cremaster muscle 
paralleled rarefaction in the myocardium, which was accompanied by a decrease in transcription levels 
not only of the transcriptional regulator HIF-1α, but also of its target genes Angpt-2, TIE-1 and TIE-2, 
Flkt-1 and MMP-9, indicating an impaired hypoxia-driven angiogenesis. Thus, experimental uremia in 
mice associates with systemic microvascular disease with rarefaction, tissue hypoxia and dysfunctional 
angiogenesis.
Chronic kidney disease (CKD) is associated with type 4 cardiorenal syndrome and an excessive mortality from 
cardiovascular disease (CVD). Uremia-specific mechanisms explaining the link between CKD and CVD are 
incompletely understood. Accumulating evidence indicates that the earliest manifestations of CVD occur at the 
level of the microcirculation1.
The microcirculation consists of networks of arterioles, capillaries, and venules with diameter less than 300 μm2. 
It provides a vast endothelial interface between the convective blood flow system and the tissue for efficient sol-
ute and gas exchange and is actively involved in vital functions of the cardiovascular system3. Permanent loss of 
endothelial homeostasis results in target organ damage4,5.
Endothelial dysfunction is a sensitive and independent predictor of future cardiovascular events6,7 and has 
been consistently observed in patients with CKD8–10. Endothelial dysfunction might be linked to structural 
defects of the microcirculation including microvascular rarefaction11. However, it is unknown whether any 
CKD-induced rarefaction is sufficient to cause functional deficits in tissue perfusion and oxygen delivery. We 
hypothesized that microvascular disease is an early systemic process driven by the severity of CKD, preceding 
changes in conduit arteries and resulting in tissue hypoxia.
1Department of Physiology, Charité Universitätsmedizin Berlin, Berlin, Germany. 2Center for Cardiovascular 
Research, Charité Universitätsmedizin Berlin, Berlin, Germany. 3Institute of Nutritional Science, University of 
Potsdam, Nuthetal, Potsdam, Germany. 4Dipartimento di Ingegneria dell’Informazione, University of Padova, 
Padova, Italy. 5Department of Pediatric Nephrology, Charité Universitätsmedizin Berlin, Berlin, Germany. Hans-
Ulrich Prommer, Johannes Maurer, Axel Radlach Pries and Uwe Querfeld contributed equally to this work. 
Correspondence and requests for materials should be addressed to U.Q. (email: Uwe.querfeld@charite.de)
Received: 12 October 2017
Accepted: 19 March 2018
Published: xx xx xxxx
OPEN
www.nature.com/scientificreports/
2SCIeNtIfIC REPORtS |  (2018) 8:5317  | DOI:10.1038/s41598-018-23663-1
We here show the profound impact of CKD on architecture and function of the microvascular network 
in-vivo.
Results
Two experimental procedures generate CKD/uremia of different severity. CKD was established 
in mice by adenine feeding or subtotal nephrectomy. A four week 0.2% adenine diet led to serum urea levels of 39 
to 475 mg/dL (median 169 mg/dL), and subtotal nephrectomy followed by a four-month uremia-inducing period 
led to urea levels of 57 to 249 mg/dL (median 62 mg/dL). For control and sham operated mice, the serum urea 
level was in the range of 21 to 91 mg/dL and 28 to 56 mg/dL, respectively. The mean urea level of uremic mice was 
250 mg/dl; we arbitrarily defined a mildly uremic range (up to 250 mg/dL) and a severely uremic range (250 to 
475 mg/dL) (Fig. 1). Applying those uremic ranges, we assigned animals to five groups: for the adenine model (1) 
controls (n = 8), (2) mildly uremic mice (n = 12), and (3) severely uremic mice (n = 7), and for the nephrectomy 
model (4) sham operated mice (n = 5), and (5) mice with subtotal nephrectomy (SNX; n = 7). The serum creati-
nine levels for these groups are shown in Supplemental Fig. 1.
Mean arterial blood pressure (MAP) measured at the day of intravital microscopy (Supplemental Fig. 2) was 
significantly higher in severely uremic mice compared to controls, but not significantly different between mildly 
uremic animals of the adenine group and their controls (p = 0.070), and SNX animals and their sham operated 
controls (p = 0.15) (Table 1).
Interleukin-6 (IL-6), a marker of inflammation, was significantly elevated in adenine-fed mice with mild 
and severe uremia compared to controls (Table 1). IL-6 levels correlated significantly with urea levels (r = 0.45; 
p = 0.012) (Supplementary Table 1).
The hematocrit was negatively associated with serum urea (r = −0.42; p = 0.008), but not significantly differ-
ent between uremic groups vs. their respective controls (Table 1).
Weight loss was observed in adenine-induced uremia (Table 1). The serum urea levels of all animals correlated 
with relative weight change (r = 0.33; p = 0.039); if analyzed separately in experimental groups, the correlation 
was confirmed in both, adenine-fed mice (r = 0.72; p = 0.0006) and SNX mice (r = 0.94; p < 0.0001). IL-6 levels 
were significantly associated with relative weight change (r = 0.41; p = 0.030; Supplementary Table 1).
CKD promotes microvascular rarefaction in a dose-dependent manner. In the adenine model, the 
mean microvascular density of controls (n = 8), expressed as accumulated length of microvessels per 1,000 µm2 of 
cremaster muscle area was 40.7 ± 8.0 µm/kµm2 (Fig. 1A). The mean microvascular density of adenine-fed uremic 
mice (n = 19) was 23.0 ± 8.4 µm/kµm2, corresponding to a mean reduction of 43%. Mean microvascular density 
was 25.9 ± 6.3 µm/1.000 µm2 (−36%, p < 0.0001) in mice with mild uremia and 19.9 ± 9.3 µm/1.000 µm2 (51%; 
p < 0,0001) and severe uremia, respectively. For the nephrectomy model, the mean microvascular density was 
44.7 ± 8.9 µm/kµm2 in sham operated mice (n = 5), and 29.7 ± 6.8 µm/kµm2 in SNX mice (n = 7), a mean reduc-
tion of 34%.
Figure 1. Microvascular density in the cremaster muscle correlates with the severity of uremia. Six-week-old 
BALB/c mice underwent a four-week adenine diet (n = 19) or 5/6 nephrectomy followed by a four-month 
uremia-inducing period (n = 7). Microvascular density was defined as accumulated length of microvessels [μm] 
per cremaster muscle area [μm²]. (A) For both uremia-inducing methods, mean microvascular density declines 
significantly (p < 0.0001, Mann-Whitney test) compared to controls (n = 8), or sham operated mice (n = 5). (B) 
Microvascular density measured as total vessel length per muscle area [µm per 1,000 µm2] in all experimental 
animals. Each column represents one studied animal, and each data point represents the microvascular density 
of about 800,000 µm2 of muscle area. (C) Serum urea and mean microvessel density are closely correlated 
(r = −0.68; p = < 0.0001, Spearman’s rank correlation coefficient).
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Microvascular density was inversely associated with the degree of experimental uremia as indicated by the 
serum urea level (r = −0.68; p < 0.0001; Fig. 1B and C). This association was observed in both models (r = −0.60 
p < 0.0001 in the adenine and r = −0.37; p < 0.01 in the 5/6 NX model). For each 100 mg/dL increase of serum 
urea, a similar mean reduction of about 15% could be observed with both experimental models (14.2% for the 
adenine model, and 15.7% for the nephrectomy model). There was no significant correlation with the serum cre-
atinine level in the adenine model or the SNX model.
Mean microvascular density was significantly correlated with IL-6 serum levels in the adenine model 
(r = −0.63; p = 0.0073), but not in the SNX model (r = −0.39; p = 0.23), and similarly, with relative weight 
change in the adenine model (r = 0.67; p = 0.0001), but not in the SNX model (r = 0.41;p = 0.18). Furthermore, 
mean vascular density was significantly associated with mean arterial blood pressure in the adenine fed mice 
(r = −0.54; p = 0.0034), but not in the SNX mice (p = 0.59). The correlation of microvascular density with these 
variables in both models combined is shown in Supplementary Table 1. In a multivariate linear regression model 
including all observations, only the degree of uremia as indicated by serum urea levels was an independent signif-
icant predictor of microvascular density (p < 0.0001), whereas all other variables correlating with density in uni-
variate regression, i.e. hematocrit (p = 0.990), weight change (p = 0.220), IL-6 (p = 0.157) and MAP (p = 0.245), 
were excluded from the model (corrected r2 = 0.502).
CKD induces a heterogeneous rarefaction pattern. Overall, microvascular rarefaction appeared 
highly heterogeneous in CKD animals (Fig. 1B). Some cremaster muscle areas revealed dramatic rarefaction 
up to complete vessel extinction, while almost no rarefaction was visible in some adjacent areas. As an example, 
one mouse with a serum urea level of 375 mg/dL had a cremaster observation area (800,000 μm2) with an almost 
physiological microvascular density of 21 µm/1,000 µm2. Yet, in a neighboring area (distance 2.02 mm), hardly any 
microvessel could be identified. However, since some degree of heterogeneity in microvascular density was also 
observed in control and sham operated mice (Fig. 1B), we analyzed the features of the CKD-induced rarefaction 
pattern by studying average segment lengths in all cremaster areas.
Loss of small coherent vessel systems is the predominant mechanism or rarefaction in CKD. In 
a theoretical model, microvascular rarefaction could proceed (A) in a homogeneous pattern of regression affect-
ing first the most abundant smallest vessels in all networks, or (B) in a heterogeneous pattern of loss of coherent 
vessel systems in some, but not other networks (Fig. 2A–C). To assess the heterogeneity of a microvascular net-
work, we determined the average segment length, i.e. the average distance between two adjacent bifurcations. 
In model A, assuming a 50% reduction of capillaries, rarefaction would lead to a significantly increased average 
segment length, but preservation of coherent vessel networks. In model B, loss of some coherent vessel networks 
would lead to increased heterogeneity, while the average segment length (of remaining networks) would remain 
nearly constant.
In our experiments, the average segment length remained almost unchanged by rarefaction (con-
trols: 116 ± 27.9 µm, mildly uremic mice 120.2 ± 22.7 µm, i.e. 3% extension) except in severely uremic mice 
(133.7 ± 23.9 µm, i.e. 15% extension; p = 0.01). Thus, the microvascular network of uremic mice was not pre-
dominantly affected by a homogeneous regression of capillaries (this would have led to an increase in segment 
length by up to 73% in the model), but rather by loss of coherent vessel systems (vascular trees) (Fig. 2D). While 
this conclusion is based on model assumptions, we further investigated the degree of rarefaction in the different 
microvascular caliber classes. All measured segments were allocated to six arbitrarily defined caliber classes: 
<8 µm, 8–16 µm, 16–32 µm, 32–64 µm, 64–128 µm and >128 µm (Fig. 2A). We found that caliber classes up to 
64 µm were most strongly affected by rarefaction, which mirrored their relative abundance, with most of the 
reduction found in the smallest caliber classes. In contrast, vessels of caliber > 64 µm were affected only to a minor 
Serum urea Body weight [g] Mean arterial pressure [mmHg]











at IM end Δ
Adenine induced uremia:
Control
(n = 8) 52 ± 20 mg/dl 22.4 ± 0.9 g 23.9 ± 0.5 g +9% 73.1 ± 2.8 mmHg 62.9 ± 5.9 mmHg −14% 44.0% ± 4.6% 516 ± 232 pg/ml
Mild uremia
(n = 12) 103 ± 55 mg/dl 21.9 ± 3.4 g 21.4 ± 4.4 g −2% 76.0 ± 2.6 mmHg 64.7 ± 2.2 mmHg −15% 44.2% ± 5.0% 900




386 ± 79 mg/dl 23.6 ± 1.2 g 19.1 ± 1.8 g −19% 79.11) ± 2.7 mmHg 68.7 ± 3.9 mmHg −13% 35.5%2) ± 7.0% 1,1994) ± 261 pg/ml
5/6 nephrectomy induced uremia:
Sham
(n = 5) 41 ± 11mg/dl 22.3 ± 1.4 g 27.0 ± 1.5 g +21% 72.8 ± 2.3 mmHg 63.7 ± 2.7 mmHg −13% 43.8% ± 3.0% 593 ± 662 pg/ml
5/6 Nx
(n = 7) 122 ± 84 mg/dl 23.2 ± 0.7 g 26.5 ± 2.2 g +14% 77.0 ± 4.8 mmHg 62.2 ± 4.4 mmHg −13% 42.9% ± 4.9% 767 ± 595 pg/ml
Table 1. Characteristics of experimental groups. 1)p = 0.005 compared to controls. 2)p = 0.015 compared to 
controls. 3)p = 0.032 compared to controls. 4)p = 0.005 compared to controls.
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extent or not at all (Supplementary Table 2, Fig. 2F), again suggesting rarefaction in CKD occurred preferentially 
in coherent networks of small vessels.
Our in-vivo study also permitted quantification of functional rarefaction, i.e. non-perfusion of intact 
microvessels. Functional rarefaction was quantified in the adenine model. We did observe temporary loss of 
perfusion, especially in vessels with a diameter < 64 µm, for a maximum duration of approximately 10 seconds, 
after which reperfusion started; about 4–6% of microvessels in mildly uremic mice and 10–13% of microvessels in 
severely uremic mice showed this pattern. Permanent non-perfusion (for >2 min.) was only seen in a very small 
fraction of microvessels (1.2% in mildly uremic and 3.9% in severely uremic mice). These observations suggest 
that functional rarefaction has only very little importance for the observed loss in microvascular density in CKD.
Microvascular rarefaction results in increased diffusion distances impairing oxygen supply. 
Since diffusion is critical for oxygen uptake in peripheral tissues, we constructed a two-dimensional digi-
tal model of the microvascular network and measured the size of intervascular areas (IVA), the diffusion dis-
tances (DD) within these IVA and their distribution (Fig. 3A–E). The size of the IVA in control animals (n = 8) 
was 4,004 ± 925 µm2, and the average DD was 11.0 ± 1.8 µm. In mildly uremic mice, the size of the IVA was 
10,542 ± 3,166 µm2 (p = 0.0003 vs. control), and the average DD was 14.8 ± 2.1 µm (p = 0.005 vs. control). In 
severely uremic mice, the size of the IVA was 17,869 ± 5,356 µm2 (p = 0.0006 vs. control), and the average DD 
was 23.0 ± 3.0 µm (p = 0.002 vs. control). Thus, microvascular rarefaction in CKD mice was associated with a 
significant increase in IVA and DD.
The DD distribution for controls (n = 8), mildly (n = 12), and severely uremic mice (n = 7) is depicted in 
Fig. 3F. For small and medium DD (0–12.5 µm), control mice had an integrated area under the distribution curve 
(AUC) of 74.5%. Hence, 74.5% of all DD of control mice were 12.5 µm or less. For the same DD range, severely 
uremic mice had an AUC of only 49.5%, a 34% decrease compared to controls. For long DD (>62.5 µm) the AUC 
was 0.2% in controls and 6.2% in severely uremic mice. Thus, severely uremic mice showed a 31-fold increase in 
long DD > 62.5 µm.
To assess whether the extension of DD impairs the oxygen supply by diffusion in IVA, we measured the maxi-
mal diffusion distance (DDmax) and calculated the maximal diffusion range (DRmax) of oxygen in the cremaster 
muscle tissue (Fig. 3D–G). The DDmax in the experimental groups was 95 µm in controls, 140 µm in mildly 
uremic and 270 µm in severely uremic mice, respectively. An estimate for DRmax can be derived from the param-
eters diffusivity, solubility, partial pressure and consumption rate of oxygen12, which varies in different tissues13. 
Figure 2. CKD-induced rarefaction is characterized by loss of coherent networks of vessel calibers <64 µm. 
(A) Model with two vessel trees, entailing arterial vessels (red), capillaries (green), and venous vessels (blue). A 
tree consists of nine vessel hierarchy levels with defined caliber ranges (<8 µm, 8 to 16 µm, 16 to 32 µm, 32 to 
64 µm, 64 to 128 µm, and >128 µm). (B) Model of homogeneous rarefaction by loss of 50% of capillaries. (C) 
Model of heterogeneous rarefaction by loss of four vascular trees. (D) In the model of homogeneous rarefaction, 
the average segment length of the microvessel system (the distance between two adjacent bifurcations) is 
increased by 73%, and in the heterogeneous rarefaction model by 7%. (E) Compared to controls, measured 
average segment lengths were not significantly increased (only by 3% in mildly uremic, and by 15% in severely 
uremic mice) despite substantial microvascular rarefaction, indicating loss of coherent microvessel networks. 
(F) Microvessel densities of controls, mildly and severely uremic mice, differentiated by caliber size. Significant 
rarefaction in the experimental groups affects predominantly microvessels with calibers <64 µm. For larger 
vessels (calibers >64 µm) rarefaction is not significant.
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The DRmax was calculated as 157 µm, 159 µm and 157 µm, respectively, for these groups (for calculations, see 
Supplementary Methods). These results compare to maximal oxygen diffusion ranges in tissue of 20 up to 200 µm, 
which have been calculated elsewhere using these equations12. Thus, DDmax values were well within the calcu-
lated DRmax in controls and mildly uremic mice, but exceeded DRmax by far in severely uremic mice (Fig. 3G). 
In this group, 4.3% of DD exceeded DRmax, indicating that this percentage of tissue was out of reach for oxygen 
supply by diffusion.
Blood flow velocity and leukocyte rolling velocity in CKD. Blood flow velocity (VB) was measured 
in microvessels of different calibers, according to caliber ranges described above (Fig. 2A). VB was significantly 
decreased in the uremic mice only in vessels of calibers >16 µm (Supplementary Figure 3A). For calibers between 
16 and 32 µm, VB of severely uremic mice was 34% below the corresponding VB of controls (p = 0.027). The 
respective difference in VB was 35% for calibers 32 to 64 µm (p = 0.024), and 36% for calibers 64 to 128 µm 
(p = 0.001). In vessels of calibers <16 µm, VB was not significantly different between severely uremic mice and 
controls (p = 0.71).
Leukocyte rolling is considered the primary interaction of white blood cells with the vascular endothelium. It 
is known that the velocity of leukocyte rolling increases with blood flow velocity and thus with increasing vessel 
diameter. In non-uremic mice (controls of adenine model and sham operated), leukocyte rolling velocities were 
measured between 15.6 and 120.1 µm/s, and in severely uremic mice between 2.4 and 75.5 µm/s, and correlated 
with vessel diameter in both groups (non-uremic mice: r = 0.76; p < 0.0001; severely uremic: r = 0.63, p < 0.0002). 
Except for vessels with calibers 32 to 64 µm, leukocyte rolling velocity was not significantly different between 
non-uremic and severely uremic mice (Supplementary Figure 3B).
CKD diminishes convective oxygen transport. The oxygen uptake rate from the microcirculation into 
the tissue is driven by three factors: (1) the blood flow velocity in microvessels, (2) the hemoglobin concentration 
(hematocrit), and (3) the arteriovenous difference in oxygen saturation of hemoglobin (avDO2). Eventually, the 
relative change in oxygen uptake is a linear function of the individual variations of these factors. To estimate 
Figure 3. Microvascular rarefaction results in increased diffusion distances impairing oxygen supply. (A,B) 
Digital microvessel reconstruction (white lines). Intervascular areas (IVA) are coded in red in perivascular 
regions, and in blue in more distant regions; decreased color intensity indicates extended diffusion distances. 
(A) Reconstructed microvascular network of a control mouse (serum urea 46 mg/dL, microvascular density 
54 µm/1,000 µm2). The largest IVA (*) has an area of 38,000 µm2, the second largest IVA (**) of 26,000 µm2. 
(B) Microvascular network of a severely uremic mouse (serum urea 450 mg/dL, microvascular density 
12 µm/1,000 µm2). The largest IVA (*) has an area of 314,000 µm2, the second largest IVA (**) has an area 
of 222,000 µm2. (C) An intervascular area (IVA) is a projection surface of the muscle tissue, enclosed by 
reconstructed vessels. (D) A smallest tissue unit (STU) is the least digitally resolvable plot of an IVA (i.e. 
one-pixel size of 0.3 µm × 0.3 µm). (E) The diffusion distance DD is the distance between an STU and its 
closest vessel contact point. (F) DD distribution curves for the three experimental groups. The area under the 
curve corresponds to the percentage share of vessel lengths of this particular caliber range (e.g. 8 to 16 µm). At 
higher levels of uremia, DDs shift from shorter to longer distances. (G) DDmax is the longest DD measured in an 
experimental group. DRmax is the calculated maximal oxygen diffusion distance in the cremaster tissue of a BALB/c 
mouse. For severely uremic mice, DDmax exceeds DRmax indicating the existence of absolute hypoxic areas.
www.nature.com/scientificreports/
6SCIeNtIfIC REPORtS |  (2018) 8:5317  | DOI:10.1038/s41598-018-23663-1
impairment of oxygen uptake under uremic conditions, we measured the uremia-driven change of each factor in 
defined arterial and venous vessels, and determined their partial impact
Blood flow velocity (Supplementary Figure 3A) and the hematocrit (Table 1) were measured as described 
above. The avDO2 between arterial and venous vessel was measured in 14 mice (3 adenine controls, 2 mice with 
mild uremia, 5 with severe uremia, 3 sham operated mice, 1 SNX). In total, 274 measuring points were included 
in the analysis. The avDO2 of the 64 to 128 µm caliber class was negatively correlated with serum urea levels 
(r = −0.87, p < 0.0001; Fig. 4A) and positively with microvessel density (r = 0.75; p = 0.002; Fig. 4B).
Importantly, variations in factors influencing oxygen uptake depend on the microvessel caliber.
Since microvessels of calibers between 64 and 128 µm comprise the largest microvessels in the cremaster 
muscle (Fig. 2A–C), and microvascular rarefaction is not significant on this level (Fig. 2F), an oxygen uptake 
impairment measured on this top level is a reasonable surrogate for the oxygen uptake impairment of the overall 
cremaster muscle. The factor variation on top level resulted in total oxygen uptake impairments of 25% (mild 
uremic mice versus controls), and 63% (severe uremic mice versus controls). Applying a physiological oxygen 
uptake rate of a rat cremaster muscle of 0.0079 cm³O2/ cm³/min to the model14 amounted to an oxygen consump-
tion rate of 0.0059 and 0.0029 cm³O2/ cm³/min, respectively. Assuming additive effects, the relative impact of the 
individual factors in a mass balance model was as follows: In mildly uremic mice, 14 percentage points (out of the 
total 25% impairment) could be attributed to diminished blood flow and 11 percentage points to the diminished 
avDO2. Hematocrit had no impact on oxygen uptake impairment under mild uremic conditions since its vari-
ation was not significant in this group. Similarly, in severely uremic mice, 27 percentage points (out of the total 
63% impairment) were attributed to reduced blood flow, 13 percentage points to the lower hematocrit, and 23 
percentage points to a decreased avDO2 (Fig. 4C and D).
CKD is associated with diminished vascular tone. Changes of the arterial diameter are dependent on 
resting vascular tone. The increase in vascular diameter was measured in 15 animals (4 controls, 5 mildly ure-
mic and 6 severely uremic) after administering acetylcholine, adenosine, papaverine, and sodium nitroprusside. 
In control mice, the relative arterial diameter increase was 15.8 ± 1.5%. Mildly uremic mice showed a diame-
ter increase of 13.2 ± 2.5% (p = 0.33 vs. controls), and severely uremic mice a diameter increase of 8.7 ± 3.6% 
(p = 0.02 vs. controls). Compared to controls, the change in diameter was reduced by 17% in mice with mild 
Figure 4. Oxygen uptake from the microcirculation is substantially impaired in CKD. (A) Arteriovenous 
difference in the oxygen saturation of hemoglobin (avDO2) between arterial and venous microvessels of 
diameters 64 µm to 128 µm was measured in controls (n = 3), mice with mild uremia (n = 2), severe uremia 
(n = 5), sham operated mice (n = 3), and SNX (n = 1). AvDO2 correlates negatively with serum urea (p < 0.0001; 
r = −0.87). (B) Microvessel density positively correlates with avDO2 (p = 0.0022; r = 0.75). (C) Oxygen 
uptake rate (O2 transition from the microcirculation into the tissue) of controls (n = 8) compared to mildly 
uremic mice (n = 12). The oxygen uptake rate is impaired by 25%. Three factors contribute to the impairment 
(assuming additive effects): (1) reduced blood flow velocity (ΔVBlood), (2) decreased hematocrit (ΔHt), (3) 
minor avDO2 (ΔavDO2). (D) Oxygen uptake rate of controls (n = 8) compared to severely uremic mice 
(n = 7), the oxygen uptake rate is impaired by 63%. Assuming additive effects, the percentage contributions 
of ΔVBlood, ΔHt and ΔavDO2 were calculated in a mass balance model based on measurements in the 64–
128 µm caliber vessels (red bars) for mildly uremic (C) and severely uremic mice (D).
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uremia and by a 45% in severely uremic animals. The change in vessel diameter correlated inversely with the 
serum urea levels (r = −0.76; p = 0.001).
Microvascular rarefaction in the myocardium parallels rarefaction in the cremaster muscle. 
Assuming a generalized microangiopathy induced by CKD, microvascular density was analyzed in the myocar-
dium of mice by an independent observer in a blinded fashion (Supplementary Figure 4). The microvascular den-
sity expressed as percentage of CD31-positive myocardial tissue area of mice with mild uremia (n = 3) and severe 
uremia (n = 6) was significantly decreased compared to controls (n = 8), corresponding to a reduction by 50.3% 
and 76%, respectively (Fig. 5A). Microvessel density in the myocardium was significantly (r = −0.73; p = 0.0022) 
associated with blood urea levels (Fig. 5B) and microvascular density in the M. cremaster (r = 0.90; p < 0.0001) 
of identical animals, suggesting parallel development of CKD-associated vessel rarefaction (Fig. 5C). We could 
not find any evidence for apoptosis or autophagy in myocardial tissue of uremic mice or controls (Supplementary 
Figure 5).
CKD induces dysfunctional angiogenesis. To further study mechanisms of microvascular changes in 
uremia, heart tissue from mice with mild (n = 10) or severe uremia (n = 6) and controls (n = 13) was analyzed by 
RT-PCR for transcription levels of genes regulating angiogenesis: the transcription factor HIF-1α, the vascular 
endothelial growth factor VEGF-A and its receptor (KDR/Flk-1), the vascular growth factors angiopoietin 1 
and 2 (Angpt-1, Angpt-2), their receptors TIE1 and TIE-2, and the matrix metalloproteinases 2 and 9 (MMP-2, 
MMP-9). We found a significant reduction in transcription levels of HIF-1α, Angpt-2, TIE-1 and TIE-2, Flkt-1 
and MMP-9. The decrease in transcription levels of all of these genes and of the Angpt-1/Anpt-2 ratio was sig-
nificantly and inversely associated with blood urea levels (HIF-1α: p = 0.0021, r = −0.55) and positively with 
Figure 5. Microvessel density of uremic mice in the myocardium declines in parallel with the density in the 
cremaster muscle. Myocardial tissue sections were stained with an monoclonal antibody against mouse CD31 
and microvascular density was expressed as percentage of positively stained area. (A) Microvessel density 
(mean + SD) in the myocardium of controls (n = 8), mildly (n = 3; *p = 0.012); and severely uremic mice 
(n = 6; **Mann Whitney test: p = 0.0007). (B) Significant inverse linear correlation of microvascular density in 
myocardium with urea (r = −0.73; p < 0.0022). (C) Close correlation of microvascular density (CD31 staining) 
in myocardium with microvascular density in the cremaster muscle measured by intravital imaging (r = 0.90; 
p < 0.0001) in identical animals. Dotted lines in (B) and (C) indicate confidence intervals.
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microvascular density in the cremaster muscle (HIF-1α: p = 0.0037, r = 0.52). Transcription levels of VEGF-1, 
Angpt-1 and MMP-2 were not significantly different from controls (Fig. 6).
Microvascular rarefaction in mice precedes macrovascular pathology. On cross sections of the 
aorta of controls and severely uremic mice, the vessel wall layers (intima, media, internal and external elastic lam-
inae, adventitia layer) could clearly be distinguished. Two tissue sections were evaluated for each animal (n = 19, 
11 uremic, 8 controls). All animals, including severely uremic mice, showed normal morphology and no calcium 
deposits by von Kossa staining (Supplementary Figure S4). The intima-media thickness of mice aortas was not 
significantly different in uremic mice and controls (48.1 ± 7.4 vs. 43.6 ± 7.1 µm; p = 0.10).
Discussion
In this in-vivo microscopy study, we found that in an incremental manner, CKD was associated with a loss of 
coherent networks of microvessels resulting in a highly heterogeneous pattern of focal microvascular rarefaction, 
and with diminished blood flow velocity, decreased vascular tone, and impaired oxygen uptake. Furthermore, 
we found corresponding levels of microvascular rarefaction in the myocardium and evidence for a dysregulated 
angiogenesis. Altogether, these findings indicate the presence of a systemic uremic microangiopathy and chronic 
tissue hypoxia.
Uremia models. Experimental uremia was induced in two well established murine models of CKD, subto-
tal nephrectomy and adenine feeding15. These models differ considerably in symptoms and severity of uremia, 
which in mice is best reflected by serum urea levels; serum creatinine levels tend to increase later after renal 
injury in mice and are much less elevated, especially in the adenine model, which results in loss of body mass16,17. 
Following subtotal nephrectomy, mice have stable decreased renal function and do not develop progressive CKD 
and are not hypertensive for up to 16 weeks18,19. In contrast, destruction of renal tissue by adenine feeding pro-
duces progressive CKD, systemic inflammation and weight loss in a time-dependent manner16,20. Importantly, 
there was a large amount of biological variation in the degree of uremia produced by both experimental proto-
cols, permitting the investigation of the effects of CKD of different severity. Microvascular density was strongly 
correlated with renal dysfunction over the whole range of urea levels, independent of the experimental model 
and other CKD-associated conditions such as anemia (hematocrit), weight loss, and inflammation (IL-6 levels). 
These data indicate that the level of renal dysfunction is the main driving force for the extent of microvascular 
rarefaction in both experimental models. However, blood pressure increased in both experimental models and 
was significantly elevated in mice with severe uremia due to adenine feeding. Therefore, although blood pressure 
was not a significant predictor of microvascular density in the multivariate analysis, it cannot be ruled out that 
increases in systemic blood pressure played a role in the development of microvascular rarefaction.
Distinct pattern of rarefaction. CKD induced a heterogeneous pattern of rarefaction, which shows simi-
larities to previous studies by Hansen-Smith et al. in hypertensive rats21; these authors described loss of microves-
sel integrity due to dissociation of endothelial and smooth muscle cells in small arterioles, occurring in focal areas 
of the microcirculation.
We found a significant reduction in total vessel length, whereas the average segment length remained almost 
unchanged. In both experimental models, CKD promoted microvascular rarefaction by loss of whole networks 
of coherent microvessel systems, not only including capillaries (caliber 8–16 µm) but also small arterioles and 
venules with caliber classes up to 64 µm. Of note, recent Microfil perfusion studies of the kidney vasculature in 
three different murine models of progressive kidney injury showed that, independent of the model, kidney injury 
was associated with a progressive reduction of renal capillaries and small arteries, up to the level of the AA inter-
lobulares, but not of larger caliber arterial vessels22. The interlobular arteries have a diameter range of 30–90 µm in 
rats23. These data and our study suggest that CKD promotes the loss of coherent vessel systems distal to the level of 
smaller arterioles, i.e. with a cutoff level about 60 µm. It is conceivable that this process originates in the supplying 
arteriole as suggested by the work of Hansen-Smith et al.21.
Diffusion distances and convective oxygen transport. Uremic mice had a significant increase 
in intravascular areas resulting in increased diffusion distances. Severely uremic mice had maximal diffusion 
Figure 6. CKD suppresses transcription levels of angiogenesis regulating genes. RNA was isolated from 
cryoconserved heart tissues from mice (adenine-induced uremia) with mild (n = 10) or severe uremia (n = 6) 
and controls (n = 13) and gene transcription levels analyzed by RT-PCR and analyzed by Kruskall-Wallis test 
with Dunn’s test for multiple comparisons post hoc. Shown are individual values (mean ± SD).
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distances exceeding the calculated maximal diffusion range for oxygen, indicating chronic hypoxic conditions for 
parts of the muscle tissue. It is conceivable that chronic hypoxia, by recruiting inflammatory cells and promoting 
tissue fibrosis24 drives a vicious circle resulting in further hypoxia and organ damage25. Thus, rarefaction could 
spread in a similar way in areas of hypoxia, and this mechanism could provide a plausible explanation for the 
observed large avascular areas.
However, microvascular rarefaction not only impaired oxygen transport by diffusion, but also convective 
oxygen transport resulting in a reduced oxygen uptake rate. The avDO2 correlated negatively with the degree 
of microvascular rarefaction, indicating that lack of capillary surface area leads to a reduced unload of oxygen 
and thus, to a converging avDO2 of arterioles and venules, i.e. functional, microvascular shunting26. Similarly, 
spontaneously hypertensive rats develop arteriovenous shunts that gradually substitute normal microvascular 
networks27. Microvascular shunting in CKD could therefore aggravate and perpetuate chronic tissue hypoxia.
Massive loss of microvessels results in an increased total peripheral resistance and deceleration of the blood 
flow, particularly at the level of arterioles. Consequently, we observed a reduced blood flow velocity in mice with 
CKD, in spite of the presence of anemia, which normally accelerates blood flow.
Impaired oxygen uptake. We calculated an oxygen uptake impairment by 25% and 63% in mildly and 
severely uremic mice, respectively, for microvessels with a diameter of 64–128 µm, mediated by reduced blood 
flow (due to rarefaction), a lower hematocrit (due to renal anemia), and a diminished avDO2 (due to rarefac-
tion and functional shunting). While these calculations are based on mathematical modeling (and not direct 
measurements of oxygen uptake) and may not be simply translatable to humans, our observations are in line 
with several studies in dialysis patients showing abnormally low peak oxygen uptake, even after normalization 
of hemoglobin levels by erythropoietin therapy; this was explained by impaired oxygen transfer to muscle tissue 
mitochondria28–30. Our study suggests that chronic hypoxic conditions may be present in peripheral tissues even 
under resting conditions, depending on the severity of uremia.
Vascular tone. Endothelium-dependent vasodilatation is impaired in uremic animals31 and in CKD 
patients32,33. We here show, that likewise, endothelium-independent maximal vasodilatation is significantly 
reduced in uremic mice and that the measured loss of vascular tone is closely associated with the severity of 
uremia. According to Hagen-Poiseuille’s law, this deprives the affected tissue of its ability to effectively regulate 
perfusion. At least three different mechanisms could explain reduced vasodilatation in CKD: (A) a reduced bio-
availability of NO could be a major contributor to altered vascular responsiveness34. However, the use of SNP, 
which delivers an excess of NO, could not normalize vascular tone, suggesting other or additional mechanisms. 
(B) Vascular remodeling could reduce vascular compliance; the maximum achievable vessel diameter would 
then be reduced. While this hypothesis requires further studies of microvascular composition in CKD, it should 
be mentioned that skin biopsies of dialysis patients showed thickening of the basement membrane and chronic 
inflammatory cell infiltration in subdermal capillaries35. (C) Finally, microvessels in uremic tissue could be per-
manently dilated (and therefore have a blunted response to vasodilators) in order to compensate for prevailing 
hypoxia by increased blood flow. This adaptive response is well described in acute and chronic hypoxia36.
Microvascular rarefaction in the heart. Depending on serum urea levels, microvessel density in cardiac 
and cremaster muscle of identical animals declined in a parallel, strongly suggesting a systemic “toxic” effect of 
uremia on the microcirculation. Although differences in local vascular density should be acknowledged37, a sys-
temic effect implies a massive loss of functioning endothelium, with severe consequences for organ perfusion and 
metabolic homeostasis. In the heart, microvascular dysfunction could explain myocardial stunning observed in 
patients after volume depletion during hemodialysis38. While the heart is particularly vulnerable, microvascular 
dysfunction could be a common pathway for the well-known progressive end-organ damage in uremic patients, 
and this link is supported by several clinical studies documenting microvascular disease and hypoxic damage to 
the cardiovascular, pulmonary, cerebrovascular, and musculoskeletal system as well as cardiac and overall sur-
vival of dialysis patients39–41.
Dysfunctional angiogenesis. A balance of angiogenesis-regulating genes is critical for maintenance of 
microcirculatory structure and function. We found a decrease in transcription levels of not only HIF-1α, the mas-
ter regulator of transcriptional responses to hypoxia, but also of its target genes Angpt-2, TIE-1 and TIE-2, Flkt-1 
and MMP-9, thus demonstrating lack of a core response to hypoxia. While VEGF transcription was not signifi-
cantly changed in CKD mice, it should be regarded as too low for the documented amount of hypoxia. However, 
Flkt-1 transcription levels were significantly decreased. Downregulation of the VEGF receptor Flkt-1 has been 
similarly observed in coronary artery endothelial cells under hypoxic conditions42, indicating impaired angio-
genic responses to VEGF in chronic hypoxia. While Ang-1 levels were unchanged, Ang-2 levels decreased sig-
nificantly in uremic mice. Ang-1 is usually considered pro-angiogenic, Ang-2 destabilizing and anti-angiogenic, 
and the Ang-1/Ang-2 ratio is thought to determine a pro-angiogenic or anti-angiogenic environment. This study 
shows an increased (pro-angiogenic) Ang-1/Ang-2 ratio in uremic animals, and similar observations were made 
in omental biopsies obtained from children with CKD11. However, the expression of the Tie-2 receptor, which 
binds both angiopoietins was significantly decreased in uremic mice, indicating disruption of angiopoietin sign-
aling with increased blood urea levels. Transcription of Tie-1, a co-regulator of Tie-2 function43, was also down-
regulated. Taken together, our study shows an incremental suppression of pro-angiogenic signaling via both, the 
VEGF axis and the Angpt-1-TIE-2 axis; this amounts to a reverse relationship between angiogenesis and hypoxia 
in CKD.
Hypoxia, inflammation and fibrosis. Although upregulation of HIF-1α is protective in acute kidney 
injury44, long-term hypoxia-driven overexpression is associated with increased kidney fibrosis45,46, suggesting that 
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downregulation of HIF-1α might be protective47,48. Prolonged hypoxia suppresses HIF-1α expression by several 
mechanisms25; therefore one explanation for dysregulation of angiogenesis in uremic mice could be an adaptive 
response to hypoxia. In addition, prolonged hypoxia may induce endothelial to mesenchymal transition, a path-
way leading to vascular dropout and fibrosis in the kidney49 and other organs50 as well as CKD induced cardiac 
fibrosis51. Finally, persistent inflammation has long been identified as a major risk factor for vascular disease in 
CKD52. Both, uremia and hypoxia, enhance the expression of a multitude of pro-inflammatory mediators, further 
contributing to oxidative stress and endothelial damage24. Taken together, these data indicate profound lack of 
compensatory mechanisms for repair of microvascular rarefaction, as part of a vicious circle of hypoxia-driven 
dysregulation of angiogenesis and further stimulation of inflammatory and fibrotic mechanisms.
Our study suggests that capillary networks could be lost by CKD-induced absence of growth-supporting 
angiogenic signals. Deficient angiogenesis could therefore be both, a cause and a consequence of microvascular 
rarefaction in CKD. However, microvascular rarefaction is likely induced and perpetuated by many other mech-
anisms, e.g. circulating antiangiogenic factors and dysfunctional or deficient endothelial progenitor cells53–55. 
Moreover, in cultured endothelial cells, uremic serum or increased inorganic phosphate may induce apoptosis, 
and carbamylated low-density lipoprotein autophagy, respectively, suggesting dose-dependent toxic effects of 
plasma components on the endothelium in CKD51,56,57. In vivo, endothelial damage could be promoted by a 
plethora of uremic toxins or urea itself 58. Thus, published evidence suggests an active CKD-induced endothelial 
damage and/or regression of microcirculatory networks, but we could neither find evidence for apoptosis nor 
autophagy in the myocardium. However, vascular rarefaction starts within days after establishing experimental 
CKD22; apoptosis, autophagy or other mechanisms inducing vascular regression59 therefore may be operative 
early in the disease and not detectable after weeks or months as in our experimental models. In fact, recent studies 
in mice have demonstrated uniform rarefaction and functional alterations in peritubular capillaries within days 
in three experimental models of CKD60.
Microangiopathy precedes macroangiopathy in mice with CKD. We show profound microvascular 
rarefaction in uremic mice in the absence of atheroma or calcifications in aortic cross-sections. Although there 
are important species differences in atherosclerosis susceptibility, limiting translation of these findings to humans, 
it is noteworthy that endothelial dysfunction is an early event in CKD and tissue biopsy studies have demon-
strated microvascular rarefaction even in children with pre-dialysis CKD11. Our findings are in line with most 
previous studies of the microcirculation in CKD. Capillary rarefaction was documented in animals with exper-
imental CKD in the myocardium and skeletal muscle37,61–63, and in CKD patients by nailfold microscopy33 and 
in the myocardium post mortem64 and in the kidney, where rarefaction of the peritubular capillaries is a typical 
feature of chronic progressive renal disease22,60 and chronic kidney allograft failure65.
Our study has several limitations. Some experiments were only performed in adenine fed mice and con-
trols and results might not apply for other animal models or humans. Urea levels were very high in adenine fed 
mice, exceeding the degree of uremia observed in most humans, and thus further limiting comparisons. Oxygen 
uptake was not measured directly, and the degree of hypoxia was inferred from calculations of vascular network 
models, which may not resemble physiological structures. It is a further limitation of our study that we did not 
perform additional morphological or functional analyses of skeletal muscle tissue. Microvascular rarefaction 
has been recognized to develop in parallel with uremic myopathy37,63, and it seems quite possible that fatigue, 
muscular inactivity, fiber atrophy, metabolic abnormalities and many other factors66 may further contribute to 
decreased oxygen supply, tissue fibrosis and microvascular rarefaction in muscle, resulting in a vicious circle. 
Finally, although the results of our study suggest the presence of systemic microvascular disease, quantitative 
differences in microvascular supply between tissues cannot be ruled out.
In conclusion, our study indicates a systemic, early, and incremental effect of CKD on the microvascular archi-
tecture and function. Microvascular rarefaction, tissue hypoxia, and dysfunctional angiogenesis are key compo-
nents of a vicious circle amplifying the significant impairment of vital functions of the microcirculation. These 
data define microvascular rarefaction and dysfunction as important therapeutic targets for future interventional 
studies in CKD patients.
Methods
Animals. In-vivo studies were performed on the microvascular network of the cremaster muscle of BALB/c 
mice. A total of 39 six week old male BALB/c mice with a weight of 17 to 25 g were obtained for Charles River 
GmbH (Sulzfeld, Germany). The animals were kept in facilities with stable environmental conditions and a 
12 hour artificial light day and night cycle.
Experimental uremia was induced by either adenine feeding or subtotal nephrectomy (SNX). In the ade-
nine model, 19 mice were fed an ROD 18 diet (LASvendi, Soest, Germany) including 0.2% adenine additive 
(Sigma-Aldrich, St. Lois, USA) for four weeks. Eight control mice received ROD 18 diet without additives. SNX 
was performed via a two stage surgical procedure. Seven mice underwent a total nephrectomy of the left kidney, 
5 control animals were sham operated. Thirty minutes prior to surgery, animals received preoperative analgesia 
(metamizol, 200 mg/kg p.o.). For surgery, they were anaesthetized with isoflurane (4%/L O2 for induction of 
anesthesia, and 1.5% to 2.0%//L O2 for maintenance of anesthesia). The right kidney was removed via a dor-
sal incision. In sham-operated animals, the respective kidneys were exposed and shifted to achieve comparable 
operative stress. On recovery, tramadol (10 mg/kg s.c) was given to cover the post‐operative period. Animals 
were observed until full recovery from anesthesia and then returned to a clean cage. For three days mice received 
tramadol (2.5 mg/100 ml p.o.) via drinking water, and were monitored closely. Body weight and health status were 
evaluated daily. After a recovery period of two weeks, mice were subjected to a 2/3 nephrectomy of the left kidney, 
with analgesia and anesthesia being the same as mentioned above. After surgery, the animals were kept under 
standardized housing conditions for a period of 4 months. Body weight was monitored on a daily basis.
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All animal experiments were approved by the Institutional Animal Care and Use Committee and the local 
state office of occupational health and technical safety (Landesamt für Gesundheit und Soziales, Berlin, reference 
G 0396/10) and carried out according to institutional guidelines.
Cremaster Muscle Preparation. For intravital microscopy purposes i.e. cremaster muscle preparation, 
mice were anesthetized with urethan i.p. (1,500 mg/kg), and ketamine i.m. (50 mg/kg). During surgery or intra-
vital microscopy, anesthesia was continuously monitored upon pedal withdrawal reflex. Appropriately, keta-
mine was replenished i.p. (half dose of initial anesthetic). Eventually for euthanasia purposes, pentobarbital i.p. 
(250 mg/kg) was administered.
All animals underwent tracheotomy to prevent airway obstruction, catheterization of the right jugular vein for 
infusion of 0.9% NaCl to maintain fluid balance as well as catheterization of the left carotid artery for continuous 
monitoring of MAP and heart rate. The scrotum was cut, the cremaster muscle exposed and fascia and connective 
tissue were cautiously removed. The muscle was mounted on the acrylic glass stage to a surface of about 1 cm² and 
covered with transparent foil (Saran, SC Johnson, Racine, USA) to minimize evaporation. The muscle tissue was 
regularly moistened using 37 °C tempered 0.9% NaCl solution.
Intravital Microscopy. The cremaster muscle’s microvasculature was visualized on a modified intravital 
microscope (Axiotech vario, Carl Zeiss, Jena, Germany) applying a saline immersion objective (20×/0.50 W) 
at transmitted light, and a 1.6× microscope optical path amplification. In observation lasting several minutes, 
vessels, blood streams, and for small vessels, the movement of individual erythrocytes or leukocytes could clearly 
be visualized. A one minute sequence of vessels and blood streams was recorded on videotape using a CCD 
(charge coupled device) Kappa Camera system (Kappa Optronics GmbH, Gleichen, Germany) connected to a 
VHS recorder (DVCAM 64 PDV-64ME, Sony, Japan).
An initial visual field of 350 × 250 μm muscle tissue area was recorded at the first major bifurcation of the 
cremasteric artery following by further visual fields resulting in a 3 × 3 matrix area of approximately 1,000 × 750 
μm (neighboring visual fields overlap of about 10 μm). In total, up to 5 cremaster areas per animal were recorded, 
corresponding to up to 45 visual fields. Distances between distinct cremaster areas were 1,720 μm horizontally 
and 2,020 μm vertically.
Analysis of Microvascular Morphology. From the VHS recorder, the analogue film was visualized on 
a monitor. Applying the Software Vision 3D, the cremaster vessel areas were manually reproduced into digi-
tal network pattern files. Microcirculatory networks were defined as microvessels with diameters below 300 µm 
including arterioles, capillaries, and venules. In a standardized coordinate system starting point and end point 
of the vessel distances, lengths, diameters, points of bifurcation, and directions of the blood stream were regis-
tered. Segment length was defined as the distance between two bifurcations. The data file was edited and statis-
tically processed in Microsoft editor Version 5.1, Micosoft Excel 2010, Matlab 2008 (MathWorks, Natick, USA), 
and Sigmaplot 12.0 (Systat Software, Inc., San Jose, USA) for statistical analysis. The microvascular density was 
defined as accumulated length of microvessels [μm] per cremaster muscle area [μm²].
Oxygen Delivery. To estimate changes in oxygen delivery, diffusion distances (DD) within the microvascu-
lar network were calculated from a two-dimensional model constructed from a total of 999 visual fields observed 
in 19 animals. A vessel-enclosed area (intervascular area, IVA) in this model thus represented an avascular region 
of the cremaster muscle, where oxygen transport is purely by diffusion. Each IVA of the digitalized microvascular 
network was subdivided into pixels (size of each pixel: 0.3 × 0.3 μm2). To calculate a DD distribution, the distance 
of each IVA pixel to the nearest microvessel contact point was measured. In addition, a color-coding algorithm 
was applied for visualization of DD ranges.
Blood Flow Velocity. The center line velocity of the blood flow of vessels (arteries and veins) with diameters 
from 12 to 110 μm was determined based on the technology of spatial correlation67. An asynchronous flash illu-
mination system (model 11360-1, Chadwick-Helmuth, El Monte, USA) was used to illuminate one half-frame 
immediately before a CCD camera executed recordings. The next flash followed after a short delay of 5.0 ms 
applied for low blood velocities, or 1.1 ms applied for high blood velocities67.
Each vessel was recorded for a period of approximately 10 seconds during constant asynchronous flash illumi-
nation. Velocities were calculated from sequences of pairs of line intensity patterns and their spatial shifts between 
the lines. Blood stream peaks or variances due to heart pulsatility were numerically averaged and the center line 
velocity was converted into a mean velocity of blood flow (VB)68.
Leukocyte Rolling Velocity. Rolling distances of leukocytes (per time of recording) were measured by the 
Vision 3D software based on recorded blood flow sequences.
Oxygen Saturation Imaging Spectroscopy. Oxygen saturation in cremaster muscle microvessels (diam-
eter range 64–128 µm) and hemoglobin levels were assessed by an imaging spectroscopy approach as described 
elsewhere69, taking advantage of changes in the hemoglobin absorption spectrum according to its oxygen satu-
ration70. This approach allows the automatic discrimination of microvessels from tissue background. The oxygen 
saturation for individual microvessels can be determined in transillumination intravital microscopy. Spectral 
analysis was performed using a monochromator / digital camera system (TILL Photonics, Gräfeling, Germany) 
with a software package (TILL Vision, TILL Photonics, Gräfeling, Germany). For the calculation of oxygen 
saturation, the SOAP software was used69. Optical densities for a wavelength of 500–600 nm were analyzed. 
Background intensities were subtracted and the concentration of hemoglobin (Hb) and oxyhemoglobin (HbO2) 
calculated after calibration with appropriate reference absorption spectra. Spectroscopic measurement of arterial 
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and venous oxygen saturation was performed in order to determine the avDO2 (arterial – venous difference in 
oxygen saturation).
Vascular Tone. To achieve a complete vascular smooth muscle relaxation, a mixture of endothelial-dependent 
(acetylcholine) and endothelial-independent vasodilatory compounds (adenosine, papaverine, sodium nitro-
prusside) was applied to the cremaster muscle preparation71. Images of the arteries were recorded from identical 
positions using a digital X/Y positioning microscopy table (Elesta Elektrotechnik AG, Switzerland) before and 
after administering the vasodilatory cocktail. To calculate the arterial tone, the ratio of the difference between 
arterial diameter of maximal relaxation (Dmax) and arterial diameter at resting state (D) divided by Dmax was 
used72.
Blood and Tissue Sample Handling. After intravital microscopy analysis, blood samples were drawn 
for further analyses and heart and aorta were harvested. Organs were immediately frozen in liquid nitrogen 
and stored at −80 °C, or preserved in phosphate-buffered formaldehyde solution 4% (Roth GmbH, Karlsruhe, 
Germany) for subsequent paraffin-embedding. Paraffin blocks were sliced in 4 or 8 µm layers with a microtome 
and used for hematoxylin-eosin or von Kossa staining. The intima-media thickness (IMT) of mice aortas was 
measured using representative von Kossa stained paraffin embedded sections. Using Image J, the distance from 
the lumen/intima edge to the media/adventitia edge of the arteries was measured at 12 different spots per section. 
The average mean of these segments was taken as mean IMT ± SD.
Quantification of microvascular density in the myocardium. Tissue imaging was performed with 
a digital microscope (Keyence BZ-9000) using the Analyzer Software®-II (Keyence, Neu-Isenburg, Germany). 
Vessels with the morphological characteristics of arterioles or venules were excluded from the analysis. After 
correction for brightness, thinness, and optical contrast, microphotographs were taken (1/350 sec., 10-fold mag-
nification). Up to 72 images were then used for a high-resolution analysis of each tissue section.
Immunohistochemistry was performed on formalin-fixed tissue sections according to standard methods. 
Dewaxed and rehydrated tissue sections were incubated in 3% hydrogen peroxide to block endogenous per-
oxidases. The heat-induced antigen retrieval was performed in a pressure cooker, using the Dako REAL Target 
Retrieval Buffer (Dako Cytomation, Glostrup, Denmark). A monoclonal antibody against mouse CD31 (1:100) 
(PECAM-1) (D8V9E) XP® Rabbit mAb was purchased from Cell Signaling, Beverly, MA, USA. Bound anti-
body was visualized with the Vector®NovaRED™ detection kit (Vector Laboratories, Burlingame, CA, USA). Cell 
nuclei were counterstained with hematoxylin, and eosin and antibody diluents without primary antibodies were 
used as respective negative controls.
Apoptosis was measured with a polyclonal antibody against mouse cleaved caspase-3 1:300 (Asp175; Rabbit 
mAb, Cell Signaling Technology) and by TUNEL staining (APOBrdU Immunohistochemistry Kit, Bio-Rad 
Laboratories, Munich, Germany). Bound antibody was visualized with the Dako detection kits (polyclonal 
goat anti-rabbit immunoglobulin/AP 1:40, Dako D0487) and liquid permanent red Dako K0640. Autophagy 
was measured with a monoclonal antibody against mouse LC3A/B 1:1000 (D3U4C) XP® Rabbit mAb, (Cell 
Signaling). Bound antibody was visualized with the Dako detection kits (polyclonal goat anti-rabbit immuno-
globulin/HRP 1:100, Dako P0448) and Vector®NovaRED™ (Vector Laboratories).
Analysis of gene expressions in the myocardium. Gene expressions in murine heart tissue were deter-
mined by quantitative real-time reverse transcription-polymerase chain reaction (RT-PCR). Cryoconserved heart 
tissues were minced in Trizol (Invitrogen) and RNA was isolated according to the manufacturer’s protocol, treated 
with DNAse to remove genomic contaminations, and further purified using RNeasy columns (Qiagen, Hilden, 
Germany). RNA transcription, RT-PCR and calculations were performed as described73. The primer sequences 
(BioTez Berlin-Buch GmbH, Berlin, Germany) are given in Supplementary Table 3.
Statistics. Numerical values were documented as mean ± SD or mean ± SEM. IBM SPSS version 23 and 
GraphPad Prism 5.01 software was used for statistical calculations. Differences between groups were tested by the 
Mann-Whitney test or Kruskall-Wallis test with Dunn’s multiple comparison test as post hoc. A p-value < 0.05 
was considered significant. Univariate correlations were calculated by Spearman’s rank correlation coefficient. 
Multiple linear regression with stepwise variable selection was applied to identify factors independently associ-
ated with microvascular density.
Data availability statement. The datasets generated during and/or analysed during the current study are 
available from the corresponding author on reasonable request.
References
 1. Gutterman, D. D. et al. The Human Microcirculation: Regulation of Flow and Beyond. Circ Res 118, 157–172 (2016).
 2. Levy, B. I., Ambrosio, G., Pries, A. R. & Struijker-Boudier, H. A. Microcirculation in hypertension: a new target for treatment? 
Circulation 104, 735–740 (2001).
 3. Pries, A. R., Secomb, T. W. & Gaehtgens, P. The endothelial surface layer. Pflugers Archiv: European journal of physiology 440, 
653–666 (2000).
 4. Vita, J. A. & Keaney, J. F. Jr. Endothelial function: a barometer for cardiovascular risk? Circulation 106, 640–642 (2002).
 5. Lockhart, C. J., Hamilton, P. K., Quinn, C. E. & McVeigh, G. E. End-organ dysfunction and cardiovascular outcomes: the role of the 
microcirculation. Clin Sci (Lond) 116, 175–190 (2009).
 6. Bonetti, P. O., Lerman, L. O. & Lerman, A. Endothelial dysfunction: a marker of atherosclerotic risk. Arterioscler Thromb Vasc Biol 
23, 168–175 (2003).
 7. Anderson, T. J. et al. Close relation of endothelial function in the human coronary and peripheral circulations. J Am Coll Cardiol 26, 
1235–1241 (1995).
www.nature.com/scientificreports/
13SCIeNtIfIC REPORtS |  (2018) 8:5317  | DOI:10.1038/s41598-018-23663-1
 8. Fliser, D. et al. The dysfunctional endothelium in CKD and in cardiovascular disease: mapping the origin(s) of cardiovascular 
problems in CKD and of kidney disease in cardiovascular conditions for a research agenda. Kidney Int Suppl (2011) 1, 6–9 (2011).
 9. London, G. M. et al. Forearm reactive hyperemia and mortality in end-stage renal disease. Kidney Int 65, 700–704 (2004).
 10. Pannier, B. et al. Postischemic vasodilation, endothelial activation, and cardiovascular remodeling in end-stage renal disease. Kidney 
Int 57, 1091–1099 (2000).
 11. Burkhardt, D. et al. Reduced Microvascular Density in Omental Biopsies of Children with Chronic Kidney Disease. PLoS One 11, 
e0166050 (2016).
 12. Pries, A. R. & Secomb, T. W. Making microvascular networks work: angiogenesis, remodeling, and pruning. Physiology (Bethesda, 
Md.) 29, 446–455 (2014).
 13. Secomb, T. W., Hsu, R., Dewhirst, M. W., Klitzman, B. & Gross, J. F. Analysis of oxygen transport to tumor tissue by microvascular 
networks. International journal of radiation oncology, biology, physics 25, 481–489 (1993).
 14. Johnson, P. C., Vandegriff, K., Tsai, A. G. & Intaglietta, M. Effect of acute hypoxia on microcirculatory and tissue oxygen levels in rat 
cremaster muscle. J Appl Physiol (1985) 98, 1177–1184 (2005).
 15. Shobeiri, N., Adams, M. A. & Holden, R. M. Vascular calcification in animal models of CKD: A review. American journal of 
nephrology 31, 471–481 (2010).
 16. Tamura, M., Aizawa, R., Hori, M. & Ozaki, H. Progressive renal dysfunction and macrophage infiltration in interstitial fibrosis in an 
adenine-induced tubulointerstitial nephritis mouse model. Histochem Cell Biol 131, 483–490 (2009).
 17. Oyama, Y. et al. High-mobility group box-1 protein promotes granulomatous nephritis in adenine-induced nephropathy. Lab Invest 
90, 853–866 (2010).
 18. Leelahavanichkul, A. et al. Angiotensin II overcomes strain-dependent resistance of rapid CKD progression in a new remnant 
kidney mouse model. Kidney Int 78, 1136–1153 (2010).
 19. Baumann, M. et al. Imatinib ameliorates fibrosis in uraemic cardiac disease in BALB/c without improving cardiac function. Nephrol 
Dial Transplant 25, 1817–1824 (2010).
 20. Santana, A. C. et al. Thalidomide suppresses inflammation in adenine-induced CKD with uraemia in mice. Nephrol Dial Transplant 
28, 1140–1149 (2013).
 21. Hansen-Smith, F. M., Morris, L. W., Greene, A. S. & Lombard, J. H. Rapid microvessel rarefaction with elevated salt intake and 
reduced renal mass hypertension in rats. Circ Res 79, 324–330 (1996).
 22. Ehling, J. et al. Quantitative Micro-Computed Tomography Imaging of Vascular Dysfunction in Progressive Kidney Diseases. J Am 
Soc Nephrol 27, 520–532 (2016).
 23. Takenaka, T. et al. Biophysical signals underlying myogenic responses in rat interlobular artery. Hypertension 32, 1060–1065 (1998).
 24. Rockey, D. C., Bell, P. D. & Hill, J. A. Fibrosis–A Common Pathway to Organ Injury and Failure. N Engl J Med 373, 96 (2015).
 25. Fu, Q., Colgan, S. P. & Shelley, C. S. Hypoxia: The Force that Drives Chronic Kidney Disease. Clin Med Res 14, 15–39 (2016).
 26. Pries, A. R., Hopfner, M., le Noble, F., Dewhirst, M. W. & Secomb, T. W. The shunt problem: control of functional shunting in normal 
and tumour vasculature. Nat Rev Cancer 10, 587–593 (2010).
 27. Murfee, W. L. & Schmid-Schonbein, G. W. Chapter 12. Structure of microvascular networks in genetic hypertension. Methods in 
enzymology 444, 271–284 (2008).
 28. Sala, E. et al. Impaired muscle oxygen transfer in patients with chronic renal failure. Am J Physiol Regul Integr Comp Physiol 280, 
R1240–1248 (2001).
 29. Marrades, R. M. et al. Cellular bioenergetics after erythropoietin therapy in chronic renal failure. J Clin Invest 97, 2101–2110 (1996).
 30. Miro, O. et al. Skeletal muscle mitochondrial function is preserved in young patients with chronic renal failure. Am J Kidney Dis 39, 
1025–1031 (2002).
 31. Mori-Kawabe, M., Yasuda, Y., Ito, M. & Matsuo, S. Reduction of NO-mediated Relaxing Effects in the Thoracic Aorta in an 
Experimental Chronic Kidney Disease Mouse Model. Journal of atherosclerosis and thrombosis 22, 845–853 (2015).
 32. Cupisti, A. et al. Responses of the skin microcirculation to acetylcholine and to sodium nitroprusside in chronic uremic patients. Int 
J Clin Lab Res 30, 157–162 (2000).
 33. Thang, O. H. et al. Capillary rarefaction in advanced chronic kidney disease is associated with high phosphorus and bicarbonate 
levels. Nephrol Dial Transplant 26, 3529–3536 (2011).
 34. Baylis, C. Nitric oxide deficiency in chronic kidney disease. Am J Physiol Renal Physiol 294, F1–9 (2008).
 35. Ichimaru, K. & Horie, A. Microangiopathic changes of subepidermal capillaries in end-stage renal failure. Nephron 46, 144–149 
(1987).
 36. Marshall, J. M. Interactions between local dilator and sympathetic vasoconstrictor influences in skeletal muscle in acute and chronic 
hypoxia. Experimental physiology 100, 1400–1411 (2015).
 37. Flisinski, M. et al. Influence of different stages of experimental chronic kidney disease on rats locomotor and postural skeletal 
muscles microcirculation. Ren Fail 30, 443–451 (2008).
 38. McIntyre, C. W. et al. Hemodialysis-induced cardiac dysfunction is associated with an acute reduction in global and segmental 
myocardial blood flow. Clin J Am Soc Nephrol 3, 19–26 (2008).
 39. Meyring-Wosten, A. et al. Intradialytic Hypoxemia and Clinical Outcomes in Patients on Hemodialysis. Clin J Am Soc Nephrol 11, 
616–625 (2016).
 40. McIntyre, C. & Crowley, L. Dying to Feel Better: The Central Role of Dialysis-Induced Tissue Hypoxia. Clin J Am Soc Nephrol 11, 
549–551 (2016).
 41. Weiner, D. E. et al. Cardiovascular disease and cognitive function in maintenance hemodialysis patients. Am J Kidney Dis 58, 
773–781 (2011).
 42. Olszewska-Pazdrak, B., Hein, T. W., Olszewska, P. & Carney, D. H. Chronic hypoxia attenuates VEGF signaling and angiogenic 
responses by downregulation of KDR in human endothelial cells. Am J Physiol Cell Physiol 296, C1162–1170 (2009).
 43. Savant, S. et al. The Orphan Receptor Tie1 Controls Angiogenesis and Vascular Remodeling by Differentially Regulating Tie2 in Tip 
and Stalk Cells. Cell Rep 12, 1761–1773 (2015).
 44. Rosenberger, C. et al. Activation of hypoxia-inducible factors ameliorates hypoxic distal tubular injury in the isolated perfused rat 
kidney. Nephrol Dial Transplant 23, 3472–3478 (2008).
 45. Higgins, D. F. et al. Hypoxia promotes fibrogenesis in vivo via HIF-1 stimulation of epithelial-to-mesenchymal transition. J Clin 
Invest 117, 3810–3820 (2007).
 46. Kimura, K. et al. Stable expression of HIF-1alpha in tubular epithelial cells promotes interstitial fibrosis. Am J Physiol Renal Physiol 
295, F1023–1029 (2008).
 47. Zhu, Q. et al. Silencing of hypoxia-inducible factor-1alpha gene attenuated angiotensin II-induced renal injury in Sprague-Dawley 
rats. Hypertension 58, 657–664 (2011).
 48. Yang, L. et al. Silencing of hypoxia inducible factor-1alpha gene attenuated angiotensin -induced abdominal aortic aneurysm in 
apolipoprotein E-deficient mice. Atherosclerosis 252, 40–49 (2016).
 49. Basile, D. P. et al. Impaired endothelial proliferation and mesenchymal transition contribute to vascular rarefaction following acute 
kidney injury. Am J Physiol Renal Physiol 300, F721–733 (2011).
 50. Piera-Velazquez, S., Mendoza, F. A. & Jimenez, S. A. Endothelial to Mesenchymal Transition (EndoMT) in the Pathogenesis of 
Human Fibrotic Diseases. J Clin Med 5 (2016).
www.nature.com/scientificreports/
1 4SCIeNtIfIC REPORtS |  (2018) 8:5317  | DOI:10.1038/s41598-018-23663-1
 51. Charytan, D. M. et al. Increased concentration of circulating angiogenesis and nitric oxide inhibitors induces endothelial to 
mesenchymal transition and myocardial fibrosis in patients with chronic kidney disease. Int J Cardiol 176, 99–109 (2014).
 52. Yilmaz, M. I., Carrero, J. J., Axelsson, J., Lindholm, B. & Stenvinkel, P. Low-grade inflammation in chronic kidney disease patients 
before the start of renal replacement therapy: sources and consequences. Clin Nephrol 68, 1–9 (2007).
 53. Tanaka, S., Tanaka, T. & Nangaku, M. Hypoxia and Dysregulated Angiogenesis in Kidney Disease. Kidney Dis (Basel) 1, 80–89 
(2015).
 54. Goligorsky, M. S., Yasuda, K. & Ratliff, B. Dysfunctional endothelial progenitor cells in chronic kidney disease. J Am Soc Nephrol 21, 
911–919 (2010).
 55. de Groot, K. et al. Uremia causes endothelial progenitor cell deficiency. Kidney international 66, 641–646 (2004).
 56. Di Marco, G. S. et al. Increased inorganic phosphate induces human endothelial cell apoptosis in vitro. Am J Physiol Renal Physiol 
294, F1381–1387 (2008).
 57. Bose, C., Shah, S. V., Karaduta, O. K. & Kaushal, G. P. Carbamylated Low-Density Lipoprotein (cLDL)-Mediated Induction of 
Autophagy and Its Role in Endothelial Cell Injury. PLoS One 11, e0165576 (2016).
 58. Lau, W. L. & Vaziri, N. D. Urea, a true uremic toxin: the empire strikes back. Clin Sci (Lond) 131, 3–12 (2017).
 59. Korn, C. & Augustin, H. G. Mechanisms of Vessel Pruning and Regression. Developmental cell 34, 5–17 (2015).
 60. Babickova, J. et al. Regardless of etiology, progressive renal disease causes ultrastructural and functional alterations of peritubular 
capillaries. Kidney Int 91, 70–85 (2017).
 61. Tornig, J. et al. Arteriolar wall thickening, capillary rarefaction and interstitial fibrosis in the heart of rats with renal failure:the effects 
of ramipril, nifedipine and moxonidine. J Am Soc Nephrol 7, 667–675 (1996).
 62. Amann, K. et al. Rats with moderate renal failure show capillary deficit in heart but not skeletal muscle. Am J Kidney Dis 30, 382–388 
(1997).
 63. Flisinski, M. et al. Decreased hypoxia-inducible factor-1alpha in gastrocnemius muscle in rats with chronic kidney disease. Kidney 
Blood Press Res 35, 608–618 (2012).
 64. Amann, K., Breitbach, M., Ritz, E. & Mall, G. Myocyte/capillary mismatch in the heart of uremic patients. J Am Soc Nephrol 9, 
1018–1022 (1998).
 65. Adair, A. et al. Peritubular capillary rarefaction and lymphangiogenesis in chronic allograft failure. Transplantation 83, 1542–1550 
(2007).
 66. Kaltsatou, A. et al. Uremic myopathy: is oxidative stress implicated in muscle dysfunction in uremia? Front Physiol 6, 102 (2015).
 67. Pries, A. R. A versatile video image analysis system for microcirculatory research. Int J Microcirc Clin Exp 7, 327–345 (1988).
 68. Pries, A. R. & Secomb, T. W. Modeling structural adaptation of microcirculation. Microcirculation 15, 753–764 (2008).
 69. Styp-Rekowska, B. et al. An imaging spectroscopy approach for measurement of oxygen saturation and hematocrit during intravital 
microscopy. Microcirculation 14, 207–221 (2007).
 70. Zijlstra, W. G., Buursma, A. & Zwart, A. Molar absorptivities of human hemoglobin in the visible spectral range. Journal of applied 
physiology: respiratory, environmental and exercise physiology 54, 1287–1291 (1983).
 71. Klotz, K. F., Gaehtgens, P. & Pries, A. R. Does luminal release of EDRF contribute to downstream microvascular tone? Pflugers 
Archiv: European journal of physiology 430, 978–983 (1995).
 72. Pries, A. R., Heide, J., Ley, K., Klotz, K. F. & Gaehtgens, P. Effect of oxygen tension on regulation of arteriolar diameter in skeletal 
muscle in situ. Microvasc Res 49, 289–299 (1995).
 73. Freise, C. & Querfeld, U. The lignan (+)-episesamin interferes with TNF-alpha-induced activation of VSMC via diminished 
activation of NF-kB, ERK1/2 and AKT and decreased activity of gelatinases. Acta Physiol (Oxf) 213, 642–652 (2015).
Acknowledgements
The advice of Helmut Habazettl, laboratory assistance by Sylvia Plog, and preliminary work by Philipp Zöller 
is gratefully acknowledged. This work was supported by institutional funds of the Department of Physiology, 
Charité Universitätsmedizin Berlin. We acknowledge support from the German Research Foundation (DFG) and 
the Open Access Publication Fund of Charité – Universitätsmedizin Berlin. 
Author Contributions
U.P., J.M., K.v.W. and R.S. performed the in-vivo experiments. C.F., K.S. and H.N. performed the in-vitro studies. 
B.R. and P.G. provided important insights into methods and outcome interpretations. A.P. and U.Q. designed and 
supervised all parts of the study. U.Q., U.P., J.M. and A.P. prepared and edited the manuscript.
Additional Information
Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-018-23663-1.
Competing Interests: The authors declare no competing interests.
Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and 
institutional affiliations.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International 
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or 
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Cre-
ative Commons license, and indicate if changes were made. The images or other third party material in this 
article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons license and your intended use is not per-
mitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the 
copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
 
© The Author(s) 2018
